In the DESTINY-Breast04 phase III trial, the effectiveness of trastuzumab deruxtecan (T-DXd) was superior to that of a physician’s choice of chemotherapy in patients diagnosed with HER2-low metastatic BC who had undergone one or two prior lines of chemotherapy [26]. Here, ERBB2 is linked to breast cancer.